Calliditas Therapeutics Future Growth
Future criteria checks 6/6
Calliditas Therapeutics is forecast to grow earnings and revenue by 49.9% and 28.9% per annum respectively. EPS is expected to grow by 50.8% per annum. Return on equity is forecast to be 87.4% in 3 years.
Key information
49.9%
Earnings growth rate
50.8%
EPS growth rate
| Pharmaceuticals earnings growth | 53.4% |
| Revenue growth rate | 28.9% |
| Future return on equity | 87.4% |
| Analyst coverage | Good |
| Last updated | 06 May 2024 |
Recent future growth updates
Recent updates
Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results
Feb 24
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Jan 12Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost
Dec 22Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?
Sep 22What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today
Aug 19Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%
May 26Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?
Feb 24Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Nov 25Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%
Aug 24Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?
Aug 03Is Calliditas Therapeutics (STO:CALTX) A Risky Investment?
Apr 24Need To Know: The Consensus Just Cut Its Calliditas Therapeutics AB (publ) (STO:CALTX) Estimates For 2022
Mar 19Analysts' Revenue Estimates For Calliditas Therapeutics AB (publ) (STO:CALTX) Are Surging Higher
Feb 28Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4,450 | 2,019 | 3,040 | 3,065 | 6 |
| 12/31/2025 | 3,163 | 1,092 | 1,314 | 1,336 | 8 |
| 12/31/2024 | 1,879 | 85 | 237 | 257 | 8 |
| 12/31/2023 | 1,207 | -466 | -447 | -435 | N/A |
| 9/30/2023 | 1,184 | -451 | -230 | -227 | N/A |
| 6/30/2023 | 1,150 | -292 | -292 | -290 | N/A |
| 3/31/2023 | 944 | -393 | -354 | -352 | N/A |
| 12/31/2022 | 803 | -412 | -314 | -311 | N/A |
| 9/30/2022 | 405 | -628 | -724 | -703 | N/A |
| 6/30/2022 | 343 | -608 | -634 | -611 | N/A |
| 3/31/2022 | 279 | -576 | -541 | -519 | N/A |
| 12/31/2021 | 229 | -500 | -484 | -462 | N/A |
| 9/30/2021 | 199 | -452 | -422 | -420 | N/A |
| 6/30/2021 | 0 | -600 | -490 | -490 | N/A |
| 3/31/2021 | 0 | -501 | -425 | -425 | N/A |
| 12/31/2020 | 1 | -433 | -309 | -309 | N/A |
| 9/30/2020 | 47 | -286 | -233 | -235 | N/A |
| 6/30/2020 | 47 | -198 | -64 | -48 | N/A |
| 3/31/2020 | 185 | -54 | -57 | -40 | N/A |
| 12/31/2019 | 185 | -33 | -87 | -71 | N/A |
| 9/30/2019 | 138 | -54 | -86 | -68 | N/A |
| 6/30/2019 | 138 | -35 | -166 | -166 | N/A |
| 3/31/2019 | N/A | -136 | -144 | -144 | N/A |
| 12/31/2018 | N/A | -132 | -128 | -128 | N/A |
| 9/30/2018 | N/A | -128 | -112 | -112 | N/A |
| 6/30/2018 | N/A | -115 | -114 | -114 | N/A |
| 3/31/2018 | N/A | -113 | -89 | -89 | N/A |
| 12/31/2017 | N/A | -87 | -68 | -68 | N/A |
| 12/31/2016 | N/A | -57 | N/A | -55 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CALTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: CALTX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CALTX is expected to become profitable in the next 3 years.
Revenue vs Market: CALTX's revenue (28.9% per year) is forecast to grow faster than the Swedish market (1.9% per year).
High Growth Revenue: CALTX's revenue (28.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CALTX's Return on Equity is forecast to be very high in 3 years time (87.4%).